BeStock  
Stocks › Biotechnology › ASND

Ascendis Pharma A/S ASND

US equityMarket cap rank #681Biotechnology
$227.46 −$0.37 (-0.16%)
Market open · Oct 1, 1:20 pm ET · After hours $227.83 0.00%
Open$228.03
Prev close$227.83
Day range$226.76 – $229.66
Volume408.7K
Market cap$14.97B
P/E (TTM)17.9
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026 · reported in EUR

Revenue€339.29M+114.7% YoY
Operating profit€220.47M+516.4% YoY
Net profit€206.97M+632.7% YoY
Diluted EPS€2.83+445.1% YoY
Free cash flow€270.73M+2,286.5% YoY
Operating cash flow€281.68M

Revenue, last 8 quarters

€57.8MSep '24€173.9MDec '24€101.0MMar '25€158.0MJun '25€213.6MSep '25€247.5MDec '25€246.6MMar '26€339.3MJun '26

Net profit, last 8 quarters

€-99.2MSep '24€-38.5MDec '24€-94.6MMar '25€-38.9MJun '25€-61.0MSep '25€-33.6MDec '25€629.3MMar '26€207.0MJun '26

Diluted EPS by quarter

-1.72Sep '24-0.64Dec '24-1.58Mar '25-0.82Jun '25-1.00Sep '25-0.55Dec '259.75Mar '262.83Jun '26

Free cash flow by quarter

€-56.6MSep '24€-87.6MDec '24€-14.3MMar '25€-12.4MJun '25€2.1MSep '25€70.0MDec '25€-7.7MMar '26€270.7MJun '26

Annual revenue

€7.0MFY20€7.8MFY21€51.2MFY22€266.7MFY23€363.6MFY24€720.1MFY25

Profitability & balance sheet

Gross margin91.3%
Operating margin25.1%
Net margin70.8%
Return on equity118.8%
Return on assets44.0%
Return on invested capital62.3%
Current ratio2.99
Liabilities / assets37.2%
Cash & investments€812.26M
Total debt€450.07M
Net cash (debt)€362.19M
Free cash flow / sales32.0%

This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.

Income statement

Line item 2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
2025 Q3
(EUR)
Total Revenue as Reported €339.29M €246.60M €720.13M €247.50M €213.63M
Total Operating Revenue €339.29M €246.60M €720.13M €247.50M €213.63M
Cost of Revenue €27.66M €17.52M €94.92M €23.60M €22.35M
Gross Profit €311.63M €229.09M €625.22M €223.90M €191.28M
Operating Expense €91.16M €204.27M €761.49M €217.46M €180.28M
Selling and Admin Expenses €171.68M €145.23M €448.04M €135.00M €111.69M
-General & Admin Expense €171.68M – €448.04M €135.00M €111.69M
Research & Development €75.89M €59.04M €303.62M €78.15M €66.88M
Depreciation & Amortization & Depletion €1.66M – €9.82M €4.31M €1.72M
-Depreciation & Amortization €1.66M – €9.82M €4.31M €1.72M
Other Operating Expenses -€158.07M – – – –
Operating Profit €220.47M €24.81M -€136.27M €6.44M €11.00M
Net Non-Operating Interest Income (Expense) -€1.03M -€62.74M -€44.88M €4.30M -€16.40M
Non-Operating Interest Income €4.83M €4.52M €15.30M €4.37M €3.33M
Non-Operating Interest Expense €14.17M €67.26M €80.65M €20.54M €19.72M
Total Other Finance Costs -€8.31M – -€20.47M – –
Other Income (Expense) €10.66M -€10.25M -€31.50M -€37.45M -€51.97M
Gain on Sale of Security €6.82M – -€47.81M -€42.23M -€44.47M
Earnings from Equity Interest €3.84M -€10.25M €16.31M €1.33M -€7.50M
Special Income (Charges) €0.00 – – – €0.00
-Less:Impairment of Capital Assets €0.00 – – – €0.00
Pretax Profit €230.09M -€48.18M -€212.65M -€26.71M -€57.37M
Tax €23.12M -€677.52M €15.38M €6.86M €3.62M
Net Profit €206.97M €629.34M -€228.03M -€33.56M -€60.99M
Profit from Continuing Operations €206.97M €629.34M -€228.03M -€33.56M -€60.99M
Net Income to Parent Company €206.97M €629.34M -€228.03M -€33.56M -€60.99M
Net Income to Common Stockholders €206.97M €629.34M -€228.03M -€33.56M -€60.99M
Basic EPS €3.22 €10.20 -€3.76 -€0.55 -€1.00
Diluted EPS €2.83 €9.75 -€3.76 -€0.55 -€1.00

Balance sheet

Line item 2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
2025 Q3
(EUR)
Total Assets €2.29B €2.00B €1.30B €1.30B €1.15B
Total Current Assets €1.39B €1.12B €1.11B €1.11B €1.02B
Cash and Cash Equivalents & Short-Term Investments €812.26M €572.82M €616.04M €616.04M €539.09M
-Cash and Cash Equivalents €812.26M €572.82M €616.04M €616.04M €539.09M
Receivables €224.10M €196.61M €157.70M €157.70M €147.25M
-Accounts Receivable €206.51M €178.68M €141.33M €141.33M €134.73M
-Taxes Receivable €1.99M €1.26M €1.78M €1.78M €2.94M
-Other Receivables €15.60M €16.67M €14.58M €14.58M €9.58M
Prepaid Assets €43.47M €38.57M €33.72M €33.72M €29.42M
Inventory €310.58M €314.34M €301.53M €301.53M €302.02M
Total Non-Current Assets €895.61M €880.94M €193.59M €193.59M €136.97M
Net PPE €135.69M €135.92M €146.48M €146.48M €101.76M
Investments and Advances €30.48M €23.56M €32.53M €32.53M €28.30M
-Long Term Equity Investment €30.48M €23.56M €32.53M €32.53M €28.30M
Non Current Accounts Receivables €26.49M €27.37M €10.87M €10.87M €3.16M
Goodwill and Other Intangible Assets €3.68M €3.69M €3.71M €3.71M €3.74M
Non-Current Deferred Assets €699.28M €690.41M – – –
Total Liabilities €849.53M €1.52B €1.47B €1.47B €1.33B
Total Current Liabilities €464.89M €1.13B €1.07B €1.07B €986.48M
Payables €116.58M €86.39M €97.08M €97.08M €80.21M
-Accounts Payable €103.92M €78.59M €90.66M €90.66M €78.60M
-Total Tax Payable €12.66M €7.81M €6.43M €6.43M €1.61M
Short-Term Debt and Capital Lease Obligation €65.43M €510.56M €486.53M €486.53M €482.28M
-Current Debt €65.43M €510.56M €486.53M €486.53M €482.28M
Current Provisions €221.41M €176.65M €166.40M €166.40M €137.78M
Current Deferred Liabilities €2.78M €5.36M €4.94M €4.94M €4.16M
Other Current Liabilities €58.69M €347.80M €314.44M €314.44M €282.06M
Total Non-Current Liabilities €384.64M €388.54M €396.00M €396.00M €342.34M
Long Term Debt and Capital Lease Obligation €384.64M €386.11M €385.25M €385.25M €331.37M
-Long Term Debt €384.64M €386.11M €385.25M €385.25M €331.37M
Non-Current Deferred Liabilities €0.00 €2.44M €10.75M €10.75M €10.97M
Total Equity €1.44B €487.97M -€162.82M -€162.82M -€174.08M
Stockholders' Equity €1.44B €487.97M -€162.82M -€162.82M -€174.08M
Capital Stock €8.89M €8.38M €8.32M €8.32M €8.28M
-Common Stock €8.89M €8.38M €8.32M €8.32M €8.28M
Additional Paid-In Capital €3.30B – – – –
Retained Earnings -€1.88B – – – –
Less: Treasury Stock €69,000.00 – – – –
Gains/Losses Not Affecting Retained Earnings €6.16M – – – –
Other Equity Interests – €479.59M -€171.14M -€171.14M -€182.36M
-Gross PPE – – €222.90M €222.90M –
-Accumulated Depreciation – – -€76.42M -€76.42M –
-Goodwill – – €3.50M €3.50M –
-Other Intangible Assets – – €215,000.00 €215,000.00 –

Cash flow

Line item 2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
2025 Q3
(EUR)
Operating Cash Flow €281.68M -€7.72M €53.90M €73.40M €2.15M
Net cash flow from continuing operations €281.68M -€7.72M €53.90M €73.40M €2.15M
Net Income from Continuing Operations €206.97M €629.34M -€228.03M -€33.56M -€60.99M
Gain/Loss from Continuing Operations -€3.82M €10.25M -€16.31M -€1.33M €7.50M
Depreciation & Depletion & Amortization €4.57M €4.22M €17.70M €4.82M €4.02M
Deferred Tax €23.12M -€677.52M €15.38M €6.86M €3.62M
Other Non-Cash Items -€8.27M €62.10M €87.06M €35.30M €60.08M
Change in Working Capital -€7.39M -€66.82M €70.96M €39.86M €24.64M
-Change in Receivables -€24.67M -€36.38M €15.59M -€9.55M -€24.91M
-Change in Inventory €3.77M -€12.81M -€5.92M €501,000.00 €1.35M
-Change in Prepaid Assets -€4.64M -€4.85M -€6.05M -€4.32M €5.07M
-Change in Payables and Accrued Expense €29.71M -€21.05M -€10.37M €22.72M -€7.53M
-Change In Other Working Capital -€11.56M €8.27M €77.72M €30.51M €50.66M
Net cash flow from investing -€2.85M -€6.75M -€8.49M -€3.39M -€53,000.00
Net Cash Flow from Continuing Investing Activities -€2.85M -€6.75M -€8.49M -€3.39M -€53,000.00
Net PPE Purchase and Sale -€11.91M €959,000.00 -€8.49M -€3.39M -€53,000.00
Net Other Investing Changes €9.05M -€7.71M – – –
Financing Cash Flow -€46.12M -€36.83M €36.33M €8.52M €38.85M
Net Cash Flow from Continuing Financing Activities -€46.12M -€36.83M €36.33M €8.52M €38.85M
Net Issuance Payments Of Debt -€8.14M -€8.58M -€21.96M -€6.83M -€6.57M
Net Common Stock Issuance -€51.56M -€51.86M -€17.40M €0.00 €0.00
Proceeds from Stock Option Exercised €18.46M €31.63M €87.08M €15.35M €45.43M
Net Other Financing Charges -€4.89M -€8.02M -€11.40M €0.00 €0.00
Ending Cash Balance €812.26M €572.82M €616.04M €616.04M €539.09M
Net Change in Cash €232.71M -€51.31M €81.74M €78.52M €40.95M
Beginning Cash Balance €572.82M €616.04M €559.54M €539.09M €494.05M
Effect of Exchange Rate Changes €6.73M €8.09M -€25.24M -€1.58M €4.09M
Free Cash Flow €270.73M -€7.72M €45.41M €70.01M €2.10M
Net Investment Purchase and Sale – – €0.00 €0.00 –

Discussion

No comments yet — be the first to weigh in on ASND.

Leave a comment

Scroll to Top